Type of Cancer: Lung
Sponsor: Mirati
Phase / Design: A Randomized Phase 3 Study of MRTX849 versus Docetaxel
Population: Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
